Terrance McGuire - 30 Nov 2023 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
04 Dec 2023, 16:05:21 UTC
Prior SEC filing
13 Sep 2023
Next SEC filing
23 May 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Lauren Crockett, Attorney-in-Fact

Key filing fact

Terrance McGuire filed Form 4 for Cyclerion Therapeutics, Inc. (CYCN) on 04 Dec 2023.

Key facts

  • This page summarizes Terrance McGuire's Form 4 filing for Cyclerion Therapeutics, Inc. (CYCN).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 04 Dec 2023, 16:05.

Change

  • Previous filing in this sequence was filed on 13 Sep 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYCN transaction

Common Stock

Award

Transaction value
$0
Shares
+5,000
Change %
+906%
Price
$0.000000
Shares after
5,552
Date
30 Nov 2023
Ownership
Direct
Footnotes
F1
CYCN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
34,866
Date
30 Nov 2023
Ownership
By Polaris Partners VIII, L.P
Footnotes
F2
CYCN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,247
Date
30 Nov 2023
Ownership
By Polaris Entrepreneurs 'Fund VIII, L.P.
Footnotes
F3
CYCN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
345
Date
30 Nov 2023
Ownership
By Bartlett Partners, LLC
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Reporting Person was granted 5,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan. 2,500 of these shares vest immediately and the remaining 2,500 of these shares vest over the next 6 months, provided that the Reporting Person remains as a director of Cylerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.

Footnote F2

The reportable securities are owned directly by Polaris Partners VIII, L.P. ("PP VIII"). Polaris Partners GP VIII, L.L.C. ("PPGP VIII") is the general partner of PP VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGP VIII. Each of David Barrett, Brian Chee, Amir Nashat and Bryce Youngren are the managing members of PPGP VIII (collectively, the "Managing Members"). Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PP VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Footnote F3

The reportable securities are owned directly by PEF VIII. PPGP VIII is the general partner of PEF VIII. The Reporting Person, a member of the Issuer's Board of Directors, is an interest holder of PPGPVIII. Each of the Reporting Person and the Managing Members, in their respective capacities with respect to PPGP VIII, may be deemed to have shared voting and dispositive power over the shares held by PEF VIII. Each of PPGP VIII, the Reporting Person and the Managing Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Footnote F4

The Reporting Person is a managing member of Bartlett Partners, LLC, the beneficial owner of the securities. The Reporting Person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .